Stockscreener 앱 받기
16.66
6.30%
-1.12
시간 외 거래:
16.66
전일 마감가:
$17.78
열려 있는:
$18.26
하루 거래량:
297.38K
Relative Volume:
2.13
시가총액:
$729.66M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.84%
1개월 성능:
+49.02%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$16.11
$18.67
1주일 범위
$14.89
$18.67
52주 변동 폭
$6.71
$18.67
Maze Therapeutics Inc Stock (MAZE) Company Profile
명칭
Maze Therapeutics Inc
전화
(650) 850-5070
주소
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
MAZE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
16.66 | 689.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 개시 | Wedbush | Outperform |
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze Therapeutics Inc. Stock Analysis and ForecastSkyrocketing returns - Autocar Professional
Is Maze Therapeutics Inc. a good long term investmentRapidly expanding wealth - Autocar Professional
What analysts say about Maze Therapeutics Inc. stockBreakthrough profits - Autocar Professional
What drives Maze Therapeutics Inc. stock priceConsistently high returns - PrintWeekIndia
how maze therapeutics inc. stock performs during market volatilityDaily Trade Opportunity - Newser
Why Maze Therapeutics Inc. stock attracts strong analyst attentionFree Real-Time Trading Opportunities - Newser
How Maze Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
What makes Maze Therapeutics Inc. stock price move sharplyProfitable Yet Secure Picks - Newser
Maze Therapeutics (NASDAQ:MAZE) Research Coverage Started at Wedbush - Defense World
Q2 Earnings Estimate for Maze Therapeutics Issued By Wedbush - Defense World
Brokerages Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Target Price at $23.50 - Defense World
Maze Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Maze Therapeutics Showcases Precision Medicine Pipeline at Major Kidney and Biotech Investor Conferences - Stock Titan
Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating - AInvest
Maze Therapeutics' Development Strategy Using Genetic Validation Seen as Promising, Wedbush Says - MarketScreener
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference - GlobeNewswire
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position - TipRanks
Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World
Contrasting Repligen (NASDAQ:RGEN) & Maze Therapeutics (NASDAQ:MAZE) - Defense World
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones - GlobeNewswire
Maze Therapeutics Q1 Earnings: Dual Clinical Programs Progress as Cash Position Hits $294M - Stock Titan
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference - The Manila Times
Maze Therapeutics CEO to Present Company Overview at 3rd Annual H.C. Wainwright BioConnect Investor Conference - Nasdaq
Maze Therapeutics Inc (MAZE)’s Day in Review: Closing at 9.25, Up by 5.23 - DWinneX
Maze Therapeutics (NASDAQ:MAZE) versus Vaxcyte (NASDAQ:PCVX) Financial Survey - Defense World
Maze Therapeutics (NASDAQ:MAZE) Shares Down 19.4% – Here’s What Happened - Defense World
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Guggenheim Reiterates Buy Rating for Maze Therapeutics (NASDAQ:MAZE) - Defense World
Leerink Partnrs Has Bearish Forecast for MAZE Q1 Earnings - Defense World
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - GlobeNewswire
Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year - TipRanks
Maze Therapeutics Inc. (MAZE) reports earnings - Quartz
Maze Therapeutics Inc (MAZE) 재무 분석
Maze Therapeutics Inc (MAZE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):